Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00424866 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 2021 to Feb 5, 2030 Start date: Dec 2020 to Oct 15, 2028 · Completion date: Jun 2022 to Dec 15, 2030 · Study site revisedv14 Show all 4 changesShow less
    • Start date: Dec 2020 to Oct 15, 2028
    • Completion date: Jun 2022 to Dec 15, 2030
    • Study site revised

    See this version in full on ClinicalTrials.gov ↗

  2. Re-verified, no change to tracked fieldsv13
  3. Primary completion date: Dec 15, 2020 to Dec 2021 Start date: Dec 1, 2019 to Dec 2020 · Completion date: Jun 2021 to Jun 2022v12 Show all 3 changesShow less
    • Start date: Dec 1, 2019 to Dec 2020
    • Completion date: Jun 2021 to Jun 2022
  4. Primary completion date: Dec 15, 2019 to Dec 15, 2020 Start date: Dec 1, 2018 to Dec 1, 2019 · Primary endpoints: 1 to 2 · Completion date: Jun 2020 to Jun 2021 · 1 morev11 Show all 5 changesShow less
    • Start date: Dec 1, 2018 to Dec 1, 2019
    • Primary endpoints: 1 to 2
    • Completion date: Jun 2020 to Jun 2021
    • Secondary endpoints expanded, about 22 words

    See this version in full on ClinicalTrials.gov ↗

  5. Start date: Jun 1, 2019 to Dec 1, 2018v10
Show 8 earlier versionsHide 8 earlier versions
  1. Study site revisedv9 Show moreShow less

    See this version in full on ClinicalTrials.gov ↗

  2. Phase: Phase 1 to Phase 1/2 Primary completion date: Dec 2014 to Dec 15, 2019 · Start date: Dec 2014 to Jun 1, 2019 · Completion date: Dec 2014 to Jun 2020 · 3 morev8 Show all 7 changesShow less
    • Primary completion date: Dec 2014 to Dec 15, 2019
    • Start date: Dec 2014 to Jun 1, 2019
    • Completion date: Dec 2014 to Jun 2020
    • Interventions: FGF-1 (Drug) to FGF-1 (Drug), Placebo (Drug)
    • Study site revised
    • Study arms: 1 to 2

    See this version in full on ClinicalTrials.gov ↗

  3. Re-verified, no change to tracked fieldsv7
  4. Start date: Dec 2013 to Dec 2014v6
  5. Primary completion date: Jul 2013 to Dec 2014 Start date: Jan 2012 to Dec 2013 · Completion date: Dec 2013 to Dec 2014v5 Show all 3 changesShow less
    • Start date: Jan 2012 to Dec 2013
    • Completion date: Dec 2013 to Dec 2014
  6. Start date: Jan 2008 to Jan 2012 Primary endpoints: 2 to 1 · Primary completion date: Jul 2013 · Completion date: Dec 2013 · 3 morev4 Show all 7 changesShow less
    • Primary endpoints: 2 to 1
    • Primary completion date: Jul 2013
    • Completion date: Dec 2013
    • Eligibility criteria expanded, about 294 words
    • Study arms: 0 to 1
    • Secondary endpoints shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  7. Start date: Aug 2007 to Jan 2008v3
  8. Start date: Jun 2007 to Aug 2007 Eligibility criteria expanded, about 224 wordsv2 Show all 2 changesShow less
    • Eligibility criteria expanded, about 224 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
FGF-1 for the treatment of patients with peripheral arterial disease with intermittent claudication.
Trial Details
NCT Number NCT00424866
Lead Sponsor Venturis Therapeutics, Inc.
Conditions Peripheral Arterial Disease, Stenosis, Intermittent Claudication
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov